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Background: Biopharmaceutical medicines represent a growing share of the global
pharmaceutical market, and with many of these biopharmaceutical products facing loss
of exclusivity rights, also biosimilars may now enter the biopharmaceutical market.
Objectives: This study aims to identify and document which investment and
development strategies are adopted by industrial players in the global biopharmaceutical
market.
Methods: A descriptive analysis was undertaken of the investment and development
strategies of the top 25 pharmaceutical companies according to 2015 worldwide
prescription drug sales. Strategies were documented by collecting data on
manufacturing plans, development programs, acquisition and collaboration agreements,
the portfolio and pipeline of biosimilar, originator and next-generation biopharmaceutical
products. Data were extracted from publicly available sources.
Results: Various investment and development strategies can be identified in the
global biopharmaceutical market: (a) development of originator biopharmaceuticals,
(b) investment in biotechnology, (c) development of next-generation biopharmaceuticals,
(d) development of biosimilars, (e) investment in emerging countries, and (f) collaboration
between companies. In the top 25 pharmaceutical companies almost every company
invests in originator biopharmaceuticals and in biotechnology in general, but only half
of them develops next-generation biopharmaceuticals. Furthermore, only half of them
invest in development of biosimilars. The companies’ biosimilar pipeline is mainly focused
on development of biosimilar monoclonal antibodies and to some extent on biosimilar
insulins. A common strategy is collaboration between companies and investment in
emerging countries.
Conclusions: A snapshot of investment and development strategies used by industrial
players in the global biopharmaceutical market shows that all top 25 pharmaceutical
companies are engaged in the biopharmaceutical market and that this industrial
landscape is diverse. Companies do not focus on a single strategy, but are involved
in multiple investment and development strategies. A common strategy to market
biopharmaceuticals is collaboration between companies. These collaborations can as
well be used to gain access in regions the company has less experience with. With
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patents expiring for some of the highest selling monoclonal antibodies, this snapshot
highlights the interest of companies to invest in the development of these molecules
and/or enter into collaborations to create access to these molecules.
Keywords: Off-patent biological medicine, biosimilar medicine, investment and development strategies,
biopharmaceutical market, pharmaceutical industry
INTRODUCTION
Totaling US$ 228 billion in global sales in 2016 (Troein,
2017), biopharmaceutical medicines represent a growing share
of the global pharmaceutical market. With many of these
biopharmaceutical products facing loss of patent protection and
other exclusivity rights, also non-innovator versions of these
molecules, biosimilars, may now enter the market, resulting
in a shift of market shares (IMS Health, 2016), revision
of strategies of companies and attraction of new players to
the biopharmaceutical market. Due to lower research and
development costs and increase in competition, biosimilars offer
a lower cost alternative to expensive biopharmaceutical therapies.
By adopting biosimilars, health care systems can expand patient
access, offermore treatment options to physicians and have a new
tool to control increasing health care expenses (IMS Institute for
Healthcare Informatics, 2016). Overall, large investments have
been made by companies to compete on the biopharmaceutical
market.
These developments are also reflected in the industrial
players in this market. Although there does not exist a
classification system of companies active in this market,
one could distinguish between big pharmaceutical companies,
biotechnological companies, generics companies, new entrants,
and companies from emerging countries. Big pharmaceutical
companies are companies like Pfizer, Merck, and J&J, which
originally focused on chemically developed medicines, and now
target the biopharmaceutical market. On the biopharmaceutical
market, there are as well biotechnological companies, like
Amgen, whose focus has been on the development of
biopharmaceutical medicines, be it initially originator medicines
and in a later phase biosimilar medicines. Generics companies,
companies originally focusing on generics, have also entered
the biosimilar market (e.g., Sandoz). New entrants are new
biotechnological companies, such as Celltrion and Samsung
Bioepis. Companies from emerging countries, like Biocon and
Dr. Reddy’s, are companies in fast-developing economies.
The aim of this original research article is to identify and
document which investment and development strategies are
adopted by industrial players in the global biopharmaceutical
market. To this effect, we distinguish between various investment
and development strategies, and exemplify these strategies for the
top 25 pharmaceutical companies. In 2012, Calo-Fernández et al.
identified different players active in the biosimilar industry and
core capabilities to enter this market, supported by three case
studies (Calo-Fernández and Martínez-Hurtado, 2012). To the
best of the authors’ knowledge, our study is the first to provide
a comprehensive snapshot of the industrial landscape of the
biopharmaceutical and biosimilar market as of December 2016. It
should be realized however that the landscape is rapidly evolving.
METHODS
A descriptive analysis was undertaken of the investment
and development strategies of the top 25 pharmaceutical
companies according to 2015 worldwide prescription drug
sales (Evaluate Pharma, 2016; Pharm Exec, 2016). Identification
of various investment and development strategies was based
on previous research (Meuwissen, 2016). Identified strategies
were further documented by collecting data on manufacturing
plans, development programs, acquisition and collaboration
agreements, the portfolio and pipeline of biosimilar, originator
and next-generation biopharmaceutical products of these
companies. Data were extracted from multiple, publicly available
sources, including a review of the literature in PubMed and
Embase over the last 5 years up to March 2016, a search of
the reference list of included articles for other relevant studies,
articles known to the authors, the website of the Generics and
Biosimilars Initiative (GaBI) journal, GaBI Online, company and
news websites. A detailed list with references consulted for each
company is available from the authors on request.
RESULTS
Based on our analysis of industrial players in the global
biopharmaceutical market, we distinguished between
the following investment and development strategies:
(a) development of originator biopharmaceuticals,
(b) investment in biotechnology, (c) development of next-
generation biopharmaceuticals, (d) development of biosimilars,
(e) investment in emerging countries, and (f) collaboration
between companies. Table 1 shows the investment and
development strategies of the top 25 pharmaceutical companies.
It shows whether the company is an originator company,
whether they invest in biotechnology via investment in their
own development program, via acquisition of biotechnological
companies, or both. The table also shows involvement in
development of next-generation biopharmaceuticals. A next-
generation biopharmaceutical is created by modifying the
structure of an existing biological molecule (via e.g., pegylation,
glycosylation) to alter pharmacokinetic or pharmacological
properties, such as half-life or bioavailability or to improve its
safety profile e.g., by reducing immunogenicity. This definition
of next-generation biopharmaceuticals does not include new
dosage forms. Subsequently, the table shows involvement in
biosimilar development. Importantly, the term biosimilar is
only applicable when strict regulatory requirements (European
Medicines Agency (EMA), Food and Drug Administration
(FDA) guidelines) are in place in the region in which it has been
approved. Table 1 also shows, the presence and investment of
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the company in emerging countries (focus on BRIC-countries:
Brazil, Russia, India, and China). The last column provides
information on collaborations between companies, this includes
also co-marketing of products. Categories are not mutually
exclusive, for example, next-generation biopharmaceuticals can
also be classified as originator biopharmaceuticals. Furthermore,
examples provided in Table 1 are not exhaustive.
The first column of Table 1 shows that 23 of the 25
companies listed (except for Mylan and Celgene) have originator
biopharmaceuticals. However, Celgene has several originator
biopharmaceuticals under development. The top 20 companies
all have originator biopharmaceuticals on the market.
Twenty-three out of 25 companies invest in biotechnology by
investing in their own development program and infrastructure.
Also 23 companies invest in biotechnology via acquisition
of biotechnological companies. Mylan did no acquisitions
or investments in its own infrastructure, its presence on
the biopharmaceutical market is limited to collaborations for
biosimilar development. Mylan is the only company in the
list that only engages in biosimilar development and is not
focusing on originator biopharmaceuticals/innovation. The top
10 companies all have originator products and invest in
biotechnology via investment in their own development program
as well as via acquisitions.
Almost every company in the top 25 invests in originator
biopharmaceuticals and in biotechnology in general, but only
half of them develops next-generation biopharmaceuticals.
Furthermore, only half of them invest in development and
marketing of biosimilars. Six companies [6, 7, 10, 18, 20, 23]
(numbers between square brackets indicate the position of the
company in Table 1) only have originator biopharmaceuticals,
and no next-generation biopharmaceuticals or biosimilars. Eight
companies [1, 4, 5, 9, 11, 13, 15, 22] invest in next-generation
biopharmaceuticals and also in biosimilars. Five companies [3,
8, 14, 16, 17] only invest in next-generation biopharmaceuticals
and not in biosimilars, six companies [2, 12, 19, 21, 24, 25] invest
in biosimilars, but not in next-generation biopharmaceuticals.
These next-generation biopharmaceuticals are often a modified
version of the companies’ own originator biopharmaceuticals.
A distinction can be made between biosimilars of less
complex molecules (insulin, follitropin, epoetin, filgrastim,
somatropin) and biosimilars of monoclonal antibodies (mAbs).
Four companies [5, 13, 15, 19] only invest in biosimilars of less
complex molecules, five companies [9, 11, 12, 24, 25] only in
biosimilars of monoclonal antibodies, and five companies [1,
2, 4, 21, 22] invest in both. When looking at the pipeline of
the companies, the focus of biosimilar development is mainly
on biosimilar monoclonal antibodies and to some extent on
biosimilar insulins. For example, Sanofi is making a biosimilar
version of insulin lispro, a product of competitor Eli Lilly,
whereas Eli Lilly has a biosimilar of Sanofi’s insulin glargine.
Twenty-two out of 25 companies are actively expanding
their presence in emerging markets. These are companies which
already have biopharmaceutical products on the market and
are focused on biopharmaceuticals. Gilead’s focus is not on
biopharmaceuticals. Celgene and Daiichi Sankyo do not market
biopharmaceuticals yet.
Collaboration between companies is a common strategy
for developing and marketing biopharmaceuticals. All but one
company in the list, Gilead [6], are collaborating with other
companies or are engaged in co-marketing. Seven companies use
all six investment and development strategies [1, 4, 5, 11, 13,
15, 22].
DISCUSSION
As shown in the study by Calo-Fernández and Martínez-
Hurtado (2012), in the 1990s big pharmaceutical companies and
generics companies developed an interest in the market segment
of biotechnology, and innovative biotechnological companies
saw the potential of biosimilars. We again looked at the
evolving industrial landscape, but now with biosimilars being an
established option for all type of companies.
This article has identified the following investment
and development strategies used by industrial players in
the global biopharmaceutical market: (a) development of
originator biopharmaceuticals, (b) investment in biotechnology,
(c) development of next-generation biopharmaceuticals,
(d) development of biosimilars, (e) investment in emerging
countries, and (f) collaboration between companies. Each of
these six investment and development strategies is discussed in
the following paragraphs.
Development of Originator
Biopharmaceuticals
Companies can look for new possibilities in diagnosis, prevention
and treatment of chronic diseases, cancer,... and choose to
develop originator biopharmaceuticals. Companies investing in
originator biopharmaceuticals will, thanks to their investment
in research and development (R&D) and new products, have
a competitive advantage over companies mainly focusing on
development of biosimilars, as they are able to charge a
premium price for their originator molecules. However, the
risk exists that the market share of the reference product
declines due to competition with biosimilars and other non-
originator products. If new originator molecules are not ready
to follow up, revenue is lost. Big pharmaceutical companies
that solely invest in innovation are companies like Roche,
GSK, AbbVie, and J&J. AbbVie owns with Humira R© one
of the highest selling medicines in the world, with global
sales in 2016 of US$ 16.1 billion (AbbVie, 2017). While
facing loss of exclusivity rights in US in December 2016 and
in Europe in 2018 (GaBI Online-Generics and Biosimilars
Initiative, 2015), a key challenge will be to retain market share
with new biopharmaceutical products. Until now, the answer
is often a new formulation with a different concentration,
which cannot be copied by biosimilar developers. Roche,
which invested in several originator monoclonal antibodies
(e.g., trastuzumab, rituximab, bevacizumab, pertuzumab), is
just faced with competition from biosimilars with the first
rituximab biosimilar being licensed in the EU, although patent
and exclusivity rights of several molecules expired years ago
(rituximab, 2013; trastuzumab, 2014) (GaBI Online-Generics
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and Biosimilars Initiative, 2015; F. Hoffmann-La Roche Ltd.,
2016). Roche, as a developer of complex molecules keeps
focusing on innovation (Roche, 2014). The company developed
subcutaneous forms of its intravenous medicines rituximab and
trastuzumab in order to increase patients’ convenience (Roche,
2016).
Investment in Biotechnology
When companies not established as biotechnological companies
(e.g., traditional, big pharmaceutical companies) wish to
enter the biopharmaceutical market, they would need the
right infrastructure and knowledge. This can be achieved
via acquisition of biotechnological companies. In this way,
they can link their image and marketing to the experience
and knowledge biotechnological companies have in developing
biopharmaceutical medicines. For instance, the acquisition of
Genentech by Roche, or MedImmune by AstraZeneca. When
companies do not invest in their own development program
or infrastructure, this can mean the company works via
contract manufacturers. Boehringer Ingelheim, as a contract
manufacturer, did no acquisitions of biotechnological companies,
but is now collaborating with several companies on the
development of biosimilars.
Development of Next-Generation
Biopharmaceuticals
As a company focusing on innovation, the development of
next-generation product Mircera R©, a long-acting epoetin,
fits in Roche’s business strategy. These next-generation
biopharmaceuticals are often characterized by higher
bioavailability, increased half-life, lower immunogenicity...
to create added value over existing products. Health care payers
and hospitals will have to assess whether these products are
cost-effective. Also Amgen, as one of the first manufacturers of
biopharmaceutical medicines, remains an important player due
to their investment in next-generation biopharmaceuticals. With
Aranesp R© (darbepoetin) and Neulasta R© (pegfilgrastim), two
products with an increased half-life relative to the originator,
Amgen can keep market shares high in the G-CSF and epoetin
market. By December 2016, four biosimilars to pegfilgrastim
were under evaluation at the EMA (Amgen, 2016; EMA, 2016).
Development of Biosimilars
Companies can choose to focus on development of biosimilars,
like Hospira (acquired by Pfizer in 2015) and Sandoz did. Sandoz,
which was first to launch a biosimilar in a highly regulated
market (Europe), has the highest market share of the biosimilar
market (figures up to 2014) (Long, 2015), with biosimilars of
somatropin, epoetin, filgrastim, and etanercept. Table 1 shows
that the focus of current biosimilar development is mainly on
biosimilar monoclonal antibodies, and insulins. This market
is not yet as developed as the biosimilar market with growth
hormone, filgrastim and epoetin. Although many companies
want a share of the biosimilar market, Merck KGaA is exploring
to sell its biosimilar business (O’Donnell and Roumeliotis,
2016). Merck US has attempted to enter the biologics market
via a biosimilar pathway, and recently entered into licensing
agreements with e.g., Samsung Bioepis (Table 1). Similarly,
Biogen, one of the first originator biotechnology companies,
is now combining their expertise with biosimilars via a joint
venture with Samsung BioLogics, Samsung Bioepis. Pfizer was
one of the first innovator companies to set up a broad biosimilar
development program (Nguyen, 2012). In addition to this, Pfizer
took over Hospira for, amongst other things, its biosimilar
portfolio.
Investment in Emerging Countries
Emerging countries can be attractive for companies to invest in,
a large market is available to supply and economic growth is
expected to rise rapidly. Companies can enter emerging countries
via collaborations with local manufacturers. Mylan, for example,
is working with Biocon, an Indian biotechnology company, to
develop biosimilar monoclonal antibodies. Companies can also
enter emerging countries by opening their own facilities or by
starting initiatives to provide access to treatment in these markets
(e.g., Roche’s patient support initiative, the “Blue Tree,” for cancer
care in India). Overall, all companies in the top 25 invest in
emerging countries. Some just not yet for biopharmaceutical
medicines.
Collaboration between Companies
Collaboration between companies has been a common strategy
for marketing pharmaceuticals for decennia, and is also used
for biopharmaceuticals. In this way, the combined experience
of companies can be used in synergy to compete on the
market. Companies can work together with biotechnological
companies from emerging countries in order to obtain a place
on the local market. For smaller biotechnological companies,
collaboration with a large, reputable pharmaceutical company
can help to increase trust in their product by physicians
and patients. The knowhow delivered by biotechnological
companies may, in combination with a well-defined market
strategy of big pharmaceutical companies, aid in enhancing the
uptake of a new product. New entrants and companies from
emerging countries may increase trust by collaborations with
established companies in the biopharmaceutical market. Another
factor that may play a role in entering into an agreement
between companies is risk sharing, where profits and losses
are shared between companies. The development cost of a
biopharmaceutical medicine is traditionally higher than that of a
chemically developed medicine, consequently failure to develop
and market a biopharmaceutical medicine may have serious
financial implications. Examples of this strategy with respect to
biosimilars are the arrangements made by new market entrants,
such as Celltrion and Samsung Bioepis, with more established
companies. Celltrion is collaborating with Hospira (Pfizer) in
different regions in the world, and with Mundipharma and
Orion in Europe. Likewise, Samsung Bioepis has a co-investment
strategy with US biotech originator company Biogen, and with
Merck US.
General Aspects
It is interesting to note that in the top 10 five companies
(50%) and in the top 25 eleven companies (44%)
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currently have not entered in the development or
marketing of biosimilars. It suggests that companies
deliberately choose whether or not to enter the biosimilar
market.
This study is subject to a number of limitations. The
analysis is limited to the top 25 pharmaceutical companies,
and new entrants like Samsung BioLogics are not (yet?) in the
top 25, although it can be argued that mostly big companies
have the resources, capacity and expertise needed to invest
in biopharmaceutical medicines. This article only gives a
static snapshot anno 2016 of a dynamic industrial landscape
and follow-up is needed to investigate changes in the global
biopharmaceutical market. In this respect, it should be noted
that now that patents of new classes of biopharmaceutical
products (e.g., mAbs in oncology) expire, many companies
revise their strategy. For instance, Amgen will, as an innovator
with originator medicines and next-generation products, focus
on the development of biosimilars of monoclonal antibodies.
Amgen will use its experience as an innovator to compete with
other biosimilar developers. Table 1 only provides a qualitative
overview of the investment and development strategies used
by different players in the biopharmaceutical market and does
not give quantitative information like sales figures and amounts
invested. Furthermore, only publicly available information was
consulted, as access to inside business information, often
confidential, was missing. It can be noted that there is a lack
of peer-reviewed scientific articles providing data on investment
and development strategies, and therefore extensive use has
been made of gray literature. The classification system is not
specific to the biopharmaceutical market. However, its broad
application can be valuable in further research and analysis
of the market of other types of medicines. To the best of
the authors’ knowledge, this is the first study to provide a
systematic overview of investment and development strategies
adopted by industrial players in the global biopharmaceutical
market.
CONCLUSION
This article presented a snapshot of investment and
development strategies used by industrial players in the
global biopharmaceutical market. This snapshot shows that
all top 25 pharmaceutical companies are engaged in the
biopharmaceutical market and that this industrial landscape is
diverse. Companies can develop biosimilars or can decide
to solely focus on innovation, can seek support from
biotechnological companies, or target emerging countries.
Companies do not focus on a single strategy, but are involved
in multiple investment and development strategies. A common
strategy to market biopharmaceutical medicines is collaboration
between companies, whether or not from different regions in the
world. These collaborations can as well be used to gain access
in regions the company has less experience with. With patents
expiring for some of the highest selling monoclonal antibodies,
this snapshot highlights the interest of companies to invest in the
development of these molecules and/or enter into collaborations
to create access to these molecules.
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